Clozapine REMS A Barrier To Treatment And Unnecessary For Safe Use, US FDA Adcomms Say

The atypical antipsychotic’s Risk Evaluation and Mitigation Strategy should be retired because the requirements for prescriber education and documentation on absolute neutrophil count monitoring are hindering access, panelists said.